A phase IIb, 12-week trial to evaluate the efficacy of tolimidone [MLR 1023] in patients with type 2 diabetes mellitus

Trial Profile

A phase IIb, 12-week trial to evaluate the efficacy of tolimidone [MLR 1023] in patients with type 2 diabetes mellitus

Planning
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2016

At a glance

  • Drugs Tolimidone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Mar 2016 According to a Melior Pharmaceuticals media release, this study was planned to advance tolimidone (MLR 1023), based upon results of its phase II trial (see CTP 700239413).
    • 17 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top